Product
Extension HER-2 vaccine
1 clinical trial
5 indications
Indication
Malignant Solid TumourIndication
Breast CancerIndication
Colorectal CancerIndication
Gastrointestinal stromal tumorIndication
Ovarian CancerClinical trial
Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like)Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2022-11-28